Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Szabadsag, Hungary Clinical Trials

A listing of Szabadsag, Hungary clinical trials actively recruiting patients volunteers.

RESULTS

Found (17) clinical trials

An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Ulcerative Colitis

Ulcerative colitis (UC) is a chronic inflammatory disease of the colon. Symptoms include bloody diarrhea, weight loss, and fever. There is no known cause or cure for UC. The aim of current UC treatments is to induce and maintain remission, to reduce the need of corticosteroids and avoid colectomy. Treatment …

Phase

0.64 miles

Learn More »

A Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study

Crohn's disease (CD) is a chronic inflammatory disease of the small bowel and colon. Symptoms commonly include bloody diarrhea, abdominal pain, weight loss, and fever. There is no known cause or cure for CD. The aim of current CD treatments is to induce and maintain remission, to reduce the need …

Phase

0.64 miles

Learn More »

Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality

The clinical trial is designed as an international, prospective, multi-centre, double-blind, parallel group, randomised, controlled, interventional trial to investigate whether a long-term therapy with i.v. iron (ferric carboxymaltosis) compared to placebo can reduce the rate of recurrent heart failure hospitalisations and cardiovascular (CV) death in patients with heart failure with …

Phase

0.64 miles

Learn More »

Durvalumab Long-Term Safety and Efficacy Study

This is a multicenter, open-label, global study that will enroll patients who are currently receiving durvalumab monotherapy, or have previously received durvalumab as monotherapy or in combination with any other approved or investigational anticancer agents, in an eligible AstraZeneca/MedImmune-sponsored clinical study.

Phase

0.64 miles

Learn More »

A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients

This study will explore 2 different doses of inotuzumab ozogamicin including the dose that is approved and a lower dose. The main purpose of this study is to evaluate whether a dose of inotuzumab ozogamicin, lower than the approved dose, could be recommended for adult patient with relapsed or refractory …

Phase

0.64 miles

Learn More »

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

The purpose of this study is to evaluate the safety and tolerability of a 3-day intravenous (IV) fosaprepitant (MK-0517) regimen for the prevention of CINV in pediatric participants scheduled to receive emetogenic chemotherapy.

Phase

0.64 miles

Learn More »

Evaluating QTc PK Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML

This is a singlearm, openlabel, Phase 4 study evaluating the effect of GO on the QTc, pharmacokinetics, safety, and immunogenicity of GO as a singleagent monotherapy in adult and pediatric patients with relapsed or refractory CD33positive AML. Approximately 50 adult (age >=18 years) and 6 pediatric (12 years =< age …

Phase

0.64 miles

Learn More »

Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis

The overall study population (Main Study and Mechanistic Sub-study) will consist of a total of 205 male and female patients aged between 18 and 40 years inclusive. Main Study The Main Study will be conducted in patients with new-onset moderate to severe plaque psoriasis not previously treated with any systemic …

Phase

0.87 miles

Learn More »

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive Metastatic Medullary Thyroid Cancer

The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC. It will test if the lower dose results in similar progression free survival (PFS) and overall response rate …

Phase

0.98 miles

Learn More »

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

This is a multi-center, open label, phase IV study to provide continued supply of pasireotide to patients being treated in a current Novartis-sponsored study and who are benefiting from treatment with pasireotide alone or in combination with another treatment for Cushing's Disease and Acromegaly . Eligible patients are to be …

Phase

1.23 miles

Learn More »